Adia Nutrition (ADIA) Current Deferred Revenue (2025 - 2026)
Adia Nutrition's (ADIA) quarterly Current Deferred Revenue came in at $218000.0 in Q1 2026, up 1457.14% quarter-over-quarter from $14000.0 in Q4 2025.
Powered by 
Analysis
Adia Nutrition (ADIA) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Adia Nutrition (ADIA) has reported Current Deferred Revenue for 2 consecutive years, with $218000.0 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $218000.0 in Q1 2026; TTM through Mar 2026 was $218000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $14000.0, changed N/A from the prior year.
- Current Deferred Revenue was $218000.0 for Q1 2026 at Adia Nutrition, up from $14000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $218000.0 in Q1 2026 and troughed at $14000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 9.96 Bn | 9.12 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.47 Bn | 5.47 Bn | - |
| 3 | Iovance Biotherapeutics | 4.64 Bn | 4.35 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.25 Bn | 2.28 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Precigen | 2.79 Bn | 2.79 Bn | 52.17 Mn |
| 7 | Beam Therapeutics | 2.58 Bn | 2.58 Bn | - |
| 8 | Sarepta Therapeutics | 2.12 Bn | 1.33 Bn | 251.87 Mn |
| 9 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
| 10 | Adia Nutrition | 11.33 Mn | 11.33 Mn | - |